Zydus Cadila gets USFDA's final approval for Betamethasone Dipropionate Ointment

15 Jul 2020 Evaluate

Zydus Cadila has received final approval from the USFDA to market Betamethasone Dipropionate Ointment USP, 0.05% (US RLD: Betamethasone Dipropionate Ointment). Betamethasone Dipropionate Ointment is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). The ointment will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.

The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.


Zydus Lifesciences Share Price

929.05 6.60 (0.72%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×